LENNOX INTERNATIONAL INC — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that LENNOX INTERNATIONAL INC filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.20B | Feb 17, 2026 |
| FY2025 | Sep 30, 2025 | $1.43B | Feb 17, 2026 |
| FY2025 | Jun 30, 2025 | $1.50B | Feb 17, 2026 |
| FY2025 | Mar 31, 2025 | $1.07B | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $5.34B | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | $4.98B | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | $4.72B | Feb 11, 2025 |
| FY2023 | Dec 31, 2021 | $4.19B | Feb 13, 2024 |
| FY2020 | Dec 31, 2020 | $914.00M | Feb 16, 2021 |
| FY2020 | Sep 30, 2020 | $1.06B | Feb 16, 2021 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $891.80M | Feb 16, 2018 |
| FY2017 | Sep 30, 2017 | $1.05B | Feb 16, 2018 |
| FY2017 | Jun 30, 2017 | $1.10B | Feb 16, 2018 |
| FY2017 | Mar 31, 2017 | $793.40M | Feb 16, 2018 |
| FY2017 | Dec 31, 2016 | $897.30M | Feb 16, 2018 |
| FY2017 | Sep 30, 2016 | $1.01B | Feb 16, 2018 |
| FY2017 | Jun 30, 2016 | $1.02B | Feb 16, 2018 |
| FY2017 | Mar 31, 2016 | $715.20M | Feb 16, 2018 |
| FY2016 | Dec 31, 2015 | $834.10M | Feb 21, 2017 |
| FY2016 | Sep 30, 2015 | $955.00M | Feb 21, 2017 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $389.30M | Feb 17, 2026 |
| FY2025 | Sep 30, 2025 | $487.20M | Feb 17, 2026 |
| FY2025 | Jun 30, 2025 | $517.50M | Feb 17, 2026 |
| FY2025 | Mar 31, 2025 | $340.90M | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $1.78B | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | $1.55B | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | $1.28B | Feb 11, 2025 |
| FY2023 | Dec 31, 2021 | $1.19B | Feb 13, 2024 |
| FY2020 | Dec 31, 2020 | $275.30M | Feb 16, 2021 |
| FY2020 | Sep 30, 2020 | $323.30M | Feb 16, 2021 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $142.50M | Feb 17, 2026 |
| FY2025 | Sep 30, 2025 | $259.90M | Feb 17, 2026 |
| FY2025 | Jun 30, 2025 | $273.90M | Feb 17, 2026 |
| FY2025 | Mar 31, 2025 | $129.60M | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $811.10M | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | $591.20M | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | $497.10M | Feb 11, 2025 |
| FY2023 | Dec 31, 2021 | $464.00M | Feb 13, 2024 |
| FY2020 | Dec 31, 2020 | $111.70M | Feb 16, 2021 |
| FY2020 | Sep 30, 2020 | $131.70M | Feb 16, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $195.80M | Feb 17, 2026 |
| FY2025 | Sep 30, 2025 | $328.80M | Feb 17, 2026 |
| FY2025 | Jun 30, 2025 | $349.00M | Feb 17, 2026 |
| FY2025 | Mar 31, 2025 | $168.00M | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $1.04B | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | $791.50M | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | $656.20M | Feb 11, 2025 |
| FY2023 | Dec 31, 2021 | $590.30M | Feb 13, 2024 |
| FY2022 | Dec 31, 2020 | $478.50M | Feb 21, 2023 |
| FY2021 | Dec 31, 2019 | $656.90M | Feb 15, 2022 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $103.40M | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $93.60M | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | $94.00M | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | $80.30M | Feb 11, 2025 |
| FY2023 | Dec 31, 2021 | $76.10M | Feb 13, 2024 |
| FY2022 | Dec 31, 2020 | $66.80M | Feb 21, 2023 |
| FY2021 | Dec 31, 2019 | $69.90M | Feb 15, 2022 |
| FY2020 | Dec 31, 2018 | $72.20M | Feb 16, 2021 |
| FY2019 | Dec 31, 2017 | $73.60M | Feb 18, 2020 |
| FY2018 | Dec 31, 2016 | $64.60M | Feb 19, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $681.40M | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $730.60M | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | $705.50M | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | $627.20M | Feb 11, 2025 |
| FY2023 | Dec 31, 2021 | $598.90M | Feb 13, 2024 |
| FY2022 | Dec 31, 2020 | $555.90M | Feb 21, 2023 |
| FY2021 | Dec 31, 2019 | $585.90M | Feb 15, 2022 |
| FY2020 | Dec 31, 2018 | $608.20M | Feb 16, 2021 |
| FY2019 | Dec 31, 2017 | $637.70M | Feb 18, 2020 |
| FY2018 | Dec 31, 2016 | $621.00M | Feb 19, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $757.60M | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $945.70M | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | $736.20M | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | $302.30M | Feb 11, 2025 |
| FY2023 | Dec 31, 2021 | $515.50M | Feb 13, 2024 |
| FY2022 | Dec 31, 2020 | $612.40M | Feb 21, 2023 |
| FY2021 | Dec 31, 2019 | $396.10M | Feb 15, 2022 |
| FY2020 | Dec 31, 2018 | $495.50M | Feb 16, 2021 |
| FY2019 | Dec 31, 2017 | $325.10M | Feb 18, 2020 |
| FY2018 | Dec 31, 2016 | $373.90M | Feb 19, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $118.80M | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $163.60M | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | $250.20M | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | $101.10M | Feb 11, 2025 |
| FY2023 | Dec 31, 2021 | $106.80M | Feb 13, 2024 |
| FY2022 | Dec 31, 2020 | $78.50M | Feb 21, 2023 |
| FY2021 | Dec 31, 2019 | $105.60M | Feb 15, 2022 |
| FY2020 | Dec 31, 2018 | $95.20M | Feb 16, 2021 |
| FY2019 | Dec 31, 2017 | $98.30M | Feb 18, 2020 |
| FY2018 | Dec 31, 2016 | $84.30M | Feb 19, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.08B | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $3.62B | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | $2.94B | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | $2.57B | Feb 11, 2025 |
| FY2023 | Dec 31, 2021 | $2.17B | Feb 13, 2024 |
| FY2022 | Dec 31, 2020 | $2.03B | Feb 21, 2023 |
| FY2021 | Dec 31, 2019 | $2.03B | Feb 15, 2022 |
| FY2020 | Dec 31, 2018 | $1.82B | Feb 16, 2021 |
| FY2019 | Dec 31, 2017 | $1.89B | Feb 18, 2020 |
| FY2018 | Dec 31, 2016 | $1.76B | Feb 19, 2019 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.92B | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $2.66B | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | $2.55B | Feb 17, 2026 |
| FY2023 | Dec 31, 2022 | $2.77B | Feb 13, 2024 |
| FY2022 | Dec 31, 2021 | $2.44B | Feb 21, 2023 |
| FY2021 | Dec 31, 2020 | $2.05B | Feb 15, 2022 |
| FY2020 | Dec 31, 2019 | $2.21B | Feb 16, 2021 |
| FY2019 | Dec 31, 2018 | $1.97B | Feb 18, 2020 |
| FY2018 | Dec 31, 2017 | $1.84B | Feb 19, 2019 |
| FY2017 | Dec 31, 2016 | $1.72B | Feb 16, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.16B | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $962.10M | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | $393.00M | Feb 17, 2026 |
| FY2025 | Dec 31, 2022 | ($203.10M) | Feb 17, 2026 |
| FY2024 | Dec 31, 2021 | ($269.00M) | Feb 11, 2025 |
| FY2023 | Dec 31, 2020 | ($17.10M) | Feb 13, 2024 |
| FY2022 | Dec 31, 2019 | ($170.20M) | Feb 21, 2023 |
| FY2021 | Dec 31, 2018 | ($149.60M) | Feb 15, 2022 |
| FY2020 | Dec 31, 2017 | $50.10M | Feb 16, 2021 |
| FY2019 | Dec 31, 2016 | $38.00M | Feb 18, 2020 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $497.20M | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $220.00M | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | $222.10M | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | $186.30M | Feb 11, 2025 |
| FY2023 | Dec 31, 2021 | $186.60M | Feb 13, 2024 |
| FY2022 | Dec 31, 2020 | $186.90M | Feb 21, 2023 |
| FY2021 | Dec 31, 2019 | $186.50M | Feb 15, 2022 |
| FY2020 | Dec 31, 2018 | $186.60M | Feb 16, 2021 |
| FY2019 | Dec 31, 2017 | $200.50M | Feb 18, 2020 |
| FY2018 | Dec 31, 2016 | $195.10M | Feb 19, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.89B | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $4.26B | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | $3.61B | Feb 17, 2026 |
| FY2023 | Dec 31, 2022 | $3.07B | Feb 13, 2024 |
| FY2022 | Dec 31, 2021 | $2.72B | Feb 21, 2023 |
| FY2021 | Dec 31, 2020 | $2.39B | Feb 15, 2022 |
| FY2020 | Dec 31, 2019 | $2.15B | Feb 16, 2021 |
| FY2019 | Dec 31, 2018 | $1.86B | Feb 18, 2020 |
| FY2018 | Jan 1, 2018 | $1.57B | Feb 19, 2019 |
| FY2018 | Dec 31, 2017 | $1.58B | Feb 19, 2019 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $34.20M | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $415.10M | Feb 17, 2026 |
| FY2024 | Dec 31, 2023 | $60.70M | Feb 11, 2025 |
| FY2023 | Dec 31, 2022 | $52.60M | Feb 13, 2024 |
| FY2022 | Dec 31, 2021 | $31.00M | Feb 21, 2023 |
| FY2021 | Dec 31, 2020 | $123.90M | Feb 15, 2022 |
| FY2020 | Dec 31, 2019 | $37.30M | Feb 16, 2021 |
| FY2019 | Dec 31, 2018 | $46.30M | Feb 18, 2020 |
| FY2019 | Dec 31, 2017 | $68.20M | Feb 18, 2020 |
| FY2019 | Dec 31, 2016 | $50.20M | Feb 18, 2020 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 4 | Feb 17, 2026 |
| FY2025 | Sep 30, 2025 | 7 | Feb 17, 2026 |
| FY2025 | Jun 30, 2025 | 7 | Feb 17, 2026 |
| FY2025 | Mar 31, 2025 | 3 | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | 22 | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | 16 | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | 13 | Feb 11, 2025 |
| FY2023 | Dec 31, 2021 | 12 | Feb 13, 2024 |
| FY2020 | Dec 31, 2020 | 2 | Feb 16, 2021 |
| FY2020 | Sep 30, 2020 | 3 | Feb 16, 2021 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 4 | Feb 17, 2026 |
| FY2025 | Sep 30, 2025 | 7 | Feb 17, 2026 |
| FY2025 | Jun 30, 2025 | 7 | Feb 17, 2026 |
| FY2025 | Mar 31, 2025 | 3 | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | 22 | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | 16 | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | 13 | Feb 11, 2025 |
| FY2023 | Dec 31, 2021 | 12 | Feb 13, 2024 |
| FY2020 | Dec 31, 2020 | 2 | Feb 16, 2021 |
| FY2020 | Sep 30, 2020 | 3 | Feb 16, 2021 |
Dividends Paid
Cash dividends distributed to common shareholders during the period. Shown as a positive value despite being a cash outflow in the SEC filing.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $173.00M | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $160.30M | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | $153.40M | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | $142.00M | Feb 11, 2025 |
| FY2023 | Dec 31, 2021 | $126.50M | Feb 13, 2024 |
| FY2022 | Dec 31, 2020 | $118.10M | Feb 21, 2023 |
| FY2021 | Dec 31, 2019 | $110.50M | Feb 15, 2022 |
| FY2020 | Dec 31, 2018 | $93.90M | Feb 16, 2021 |
| FY2019 | Dec 31, 2017 | $79.70M | Feb 18, 2020 |
| FY2018 | Dec 31, 2016 | $69.00M | Feb 19, 2019 |